ILV-094

DRUG5 trials

Sponsors

Wyeth is now a wholly owned subsidiary of Pfizer, Pfizer, Rockefeller University

Conditions

Atopic DermatitisHealthyPsoriasisRheumatoid Arthritis

Phase 1

Study of the Safety, Tolerability, PK, and PD of ILV-094 Administered IV or SC to Healthy Subjects

CompletedNCT00434746

Wyeth is now a wholly owned subsidiary of PfizerHealthy

Start: 2007-01-31End: 2008-02-29Target: 56Updated: 2009-07-10

Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects

CompletedNCT00447681

Wyeth is now a wholly owned subsidiary of PfizerHealthy

Start: 2006-12-31End: 2007-11-30Target: 56Updated: 2007-12-13

Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis

CompletedNCT00563524

Wyeth is now a wholly owned subsidiary of PfizerPsoriasis

Start: 2007-12-20End: 2010-06-14Updated: 2024-08-23

Phase 2

Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis

CompletedNCT00883896

PfizerRheumatoid Arthritis

Start: 2009-06-18End: 2011-02-18Updated: 2022-10-21

Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis

CompletedNCT01941537

Rockefeller UniversityAtopic Dermatitis

Start: 2013-10-31End: 2019-01-31Updated: 2019-05-07